Appointment dossier — Neuroblastoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Neuroblastoma
No studies or cited compounds on file for this cancer yet.
Open recruiting trials (18)
- NCT05770037 · Phase 2 / Phase 3 — DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers (United Kingdom)
- NCT07549321 · Phase 2 / Phase 3 — A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients (United States)
- NCT05296564 · Phase 1 / Phase 2 — Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers (Israel)
- NCT04903899 · Phase 2 — 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma (Denmark)
- NCT03363373 · Phase 2 — Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow (United States)
- NCT05642455 · Phase 1 / Phase 2 — SPEARHEAD-3 Pediatric Study (United States)
- NCT06933394 · Phase 2 — Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma (China)
- NCT05754684 · Phase 2 — Quadruple Immunotherapy for Neuroblastoma (Hong Kong)
- NCT05135975 · Phase 2 — A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors (United States)
- NCT06013618 · Phase 2 — Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma (China)
- NCT07399821 · Phase 1 / Phase 2 — An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma (Netherlands)
- NCT07318831 · Phase 2 — Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children (China)
- NCT06803875 · Phase 1 / Phase 2 — Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma (United States)
- NCT00107289 · Phase 2 — Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma (United States)
- NCT06625190 · Phase 1 / Phase 2 — Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors (United States)
- NCT07584499 · Phase 1 — Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors (China)
- NCT05272371 · Phase 1 — Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neuroblastoma Refractory to Standard Therapy and With Relapsed or Progressive Disease (Poland)
- NCT05562024 · Phase 1 — TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma (China)
Most-relevant first: trials that name Neuroblastoma, then broader trials you may still qualify for. 114 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Questions to ask your oncologist
- Of the open trials I found (for example NCT05770037), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?